Cargando…
Sarcosine May Induce EGF Production or Inhibit the Decline in EGF Concentrations in Patients with Chronic Schizophrenia (Results of the PULSAR Study)
Sarcosine (N-methylglycine), a glutamatergic modulator, reduces the primary negative symptoms of schizophrenia. These beneficial changes might be mediated by trophic factors such as epidermal growth factor (EGF). We assessed associations between initial serum EGF levels or changes in serum EGF level...
Autores principales: | Pawlak, Agnieszka, Kaczmarek, Bartosz, Wysokiński, Adam, Strzelecki, Dominik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674361/ https://www.ncbi.nlm.nih.gov/pubmed/38004423 http://dx.doi.org/10.3390/ph16111557 |
Ejemplares similares
-
MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study)
por: Strzelecki, Dominik, et al.
Publicado: (2016) -
Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex
por: Strzelecki, Dominik, et al.
Publicado: (2015) -
Two grams of sarcosine in schizophrenia – is it too much? A potential role of glutamate-serotonin interaction
por: Strzelecki, Dominik, et al.
Publicado: (2014) -
Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study
por: Strzelecki, Dominik, et al.
Publicado: (2015) -
Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease
por: Lim, Nicholas S., et al.
Publicado: (2016)